BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 30120913)

  • 1. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
    Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
    Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
    Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
    J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NanoString technology distinguishes anti-TIF-1γ
    Preusse C; Eede P; Heinzeling L; Freitag K; Koll R; Froehlich W; Schneider U; Allenbach Y; Benveniste O; Schänzer A; Goebel HH; Stenzel W; Radke J
    Brain Pathol; 2021 May; 31(3):e12957. PubMed ID: 34043263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.
    Kang EH; Kuwana M; Okazaki Y; Lee EY; Lee YJ; Lee EB; Song YW
    Mod Rheumatol; 2014 Nov; 24(6):945-8. PubMed ID: 24670134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy.
    Harada Y; Tominaga M; Iitoh E; Kaieda S; Koga T; Fujimoto K; Chikasue T; Obara H; Kakuma T; Ida H; Kawayama T; Hoshino T
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
    Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
    Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
    Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Tincani A; Selmi C; Chan JY; Chan EK; Satoh M; Franceschini F
    Clin Exp Rheumatol; 2014; 32(6):891-7. PubMed ID: 25151986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
    Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
    Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.
    Kang EH; Nakashima R; Mimori T; Kim J; Lee YJ; Lee EB; Song YW
    BMC Musculoskelet Disord; 2010 Sep; 11():223. PubMed ID: 20875136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice.
    Mariscal A; Milán M; Baucells A; Martínez MA; Guillen AG; Trallero-Araguás E; Alvarado-Cardenas M; Martínez-Martínez L; Alserawan L; Franco-Leyva T; Sanz-Martínez MT; Viñas-Giménez L; Corominas H; Juárez C; Castellví I; Selva-O'Callaghan A
    Front Immunol; 2020; 11():625896. PubMed ID: 33613568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.
    Troyanov Y; Targoff IN; Payette MP; Raynauld JP; Chartier S; Goulet JR; Bourré-Tessier J; Rich E; Grodzicky T; Fritzler MJ; Joyal F; Koenig M; Senécal JL
    Medicine (Baltimore); 2014 Nov; 93(24):318-332. PubMed ID: 25500701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
    Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
    Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria.
    Didona D; Juratli HA; Scarsella L; Keber U; Eming R; Hertl M
    Eur J Dermatol; 2020 Jun; 30(3):279-288. PubMed ID: 32666928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report.
    Kishi T; Tani Y; Okiyama N; Mizuochi K; Ichimura Y; Harigai M; Nagata S; Miyamae T
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):34. PubMed ID: 33740993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
    Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
    Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.